Centessa Pharmaceuticals plc (CNTA)
Jun 24, 2026 - CNTA was delisted (reason: acquired by LLY)
40.50
+0.32 (0.80%)
Inactive · Last trade price on Jun 23, 2026
Centessa Pharmaceuticals Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '20 Dec 31, 2020 |
Cash & Equivalents | 62.43 | 61.3 | 383.22 | 128.03 | 393.64 | 5 |
Short-Term Investments | 214.16 | 233.28 | 98.96 | 128.52 | - | - |
Cash & Short-Term Investments | 276.59 | 294.58 | 482.18 | 256.55 | 393.64 | 5 |
Cash Growth | -2.78% | -38.91% | 87.95% | -34.83% | 7768.16% | - |
Other Receivables | 56.43 | 53.92 | 43.77 | 37.82 | 24.17 | - |
Total Trade Receivables | 56.43 | 53.92 | 43.77 | 37.82 | 24.17 | - |
Other Current Assets | 15.66 | 19.38 | 10.46 | 20.73 | 19.94 | 0.01 |
Total Current Assets | 348.68 | 367.88 | 536.41 | 315.09 | 437.75 | 5.01 |
Net Property, Plant & Equipment | 10.52 | 10.85 | 11.76 | 12.95 | 1.17 | - |
Long-Term Investments | 257.12 | 282.55 | - | - | - | - |
Other Long-Term Assets | 25.45 | 26.22 | 28.63 | 32.2 | 5.39 | 0.25 |
Total Assets | 641.76 | 687.5 | 576.8 | 360.25 | 444.31 | 5.26 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '20 Dec 31, 2020 |
Accounts Payable | 10.66 | 7.58 | 7.14 | 11.82 | 13.84 | 0.02 |
Accrued Expenses | 25.92 | 35.35 | 50.86 | 27.57 | 24.5 | 3.46 |
Short-Term Debt | - | - | - | - | - | 4.17 |
Other Current Liabilities | - | - | - | - | - | 0.83 |
Total Current Liabilities | 36.57 | 42.94 | 58 | 39.39 | 38.34 | 8.48 |
Long-Term Debt | 110.44 | 110.1 | 108.94 | 75.7 | 69.8 | - |
Long-Term Leases | 7.37 | 7.57 | 8.29 | 8.89 | - | - |
Other Long-Term Liabilities | 0.03 | 0.03 | 0.03 | 0.03 | - | - |
Total Long-Term Liabilities | 117.84 | 117.7 | 117.26 | 84.62 | 69.8 | - |
Total Liabilities | 154.42 | 160.63 | 175.25 | 124 | 108.14 | 8.48 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '20 Dec 31, 2020 |
Common Stock | 0.42 | 0.41 | 0.36 | 0.27 | 0.27 | 0.02 |
Additional Paid-in Capital | 1,751 | 1,710 | 1,386 | 987.42 | 939.26 | - |
Accumulated Other Comprehensive Income | 1.41 | 2.71 | 4.21 | 1.49 | -1.5 | -0.09 |
Retained Earnings | -1,265 | -1,186 | -988.7 | -752.95 | -601.86 | -3.15 |
Shareholders' Equity | 487.35 | 526.86 | 401.55 | 236.24 | 336.17 | -3.21 |
Total Liabilities & Equity | 641.76 | 687.5 | 576.8 | 360.25 | 444.31 | 5.26 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '20 Dec 31, 2020 |
Total Debt | 117.81 | 117.67 | 117.23 | 84.59 | 69.8 | 4.17 |
Net Cash (Debt) | 158.78 | 176.91 | 364.95 | 171.96 | 323.84 | 0.83 |
Net Cash Growth | -5.00% | -51.52% | 112.23% | -46.90% | 38823.56% | - |
Net Cash Per Share | 1.13 | 1.30 | 3.19 | 1.79 | 3.47 | 0.21 |
Book Value | 487.35 | 526.86 | 401.55 | 236.24 | 336.17 | -3.21 |
Book Value Per Share | 3.46 | 3.88 | 3.51 | 2.46 | 3.60 | -0.82 |
Tangible Book Value | 487.35 | 526.86 | 401.55 | 236.24 | 336.17 | -3.21 |
Tangible Book Value Per Share | 3.46 | 3.88 | 3.51 | 2.46 | 3.60 | -0.82 |